Spero Therapeutics, Inc. Proceeds from Common Stock Issued
Spero Therapeutics, Inc. (SPRO) reported Proceeds from Common Stock Issued of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-03-27
- Spero Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2023-12-31 was $1.00K.
- Spero Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2023-09-30 was $220.00K, a 96.41% decline year-over-year.
- Spero Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Spero Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2023 was $221.00K.
- Spero Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2021 was $7.83M, a 40.52% decline from fiscal 2020.
- Spero Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2020 was $13.17M, a 16.62% decline from fiscal 2019.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 10-K · filed 2025-03-27 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | |||
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $221.00K derived: sum of 2 quarters · filed 2025-03-27 | $221.00K derived: sum of 3 quarters · filed 2025-03-27 | $221.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $220.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $220.00K derived: sum of 2 quarters · filed 2024-11-14 | $220.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2022-09-30 | $6.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $6.71M derived: sum of 2 quarters · filed 2023-11-13 | $10.33M 10-Q · filed 2023-11-13 | $12.81M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $577.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $4.20M 10-Q · filed 2023-08-10 | $6.68M derived: sum of 3 quarters · filed 2023-08-10 | $7.78M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.63M 10-Q · filed 2023-05-11 | $6.10M derived: sum of 2 quarters · filed 2023-05-11 | $7.20M derived: sum of 3 quarters · filed 2023-05-11 | $7.20M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $3.58M derived: sum of 2 quarters · filed 2022-11-14 | $3.58M derived: sum of 3 quarters · filed 2022-11-14 | $7.83M 10-K · filed 2022-03-31 |
| 2021-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.10M derived: sum of 2 quarters · filed 2022-11-14 | $5.36M 10-Q · filed 2022-11-14 | $9.36M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $4.25M 10-Q · filed 2022-08-10 | $8.26M derived: sum of 3 quarters · filed 2022-08-10 | $10.15M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $4.25M 10-Q · filed 2022-05-16 | $8.26M derived: sum of 2 quarters · filed 2022-05-16 | $10.15M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $5.89M derived: sum of 2 quarters · filed 2022-03-31 | $13.17M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $9.16M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $7.27M 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $5.54M derived: sum of 2 quarters · filed 2021-03-11 | $14.27M derived: sum of 3 quarters · filed 2021-03-11 | $15.79M 10-K · filed 2021-03-11 |
| 2019-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $8.76M derived: sum of 2 quarters · filed 2020-11-05 | $10.29M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $8.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $10.25M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $1.52M 10-Q · filed 2020-05-08 | |||
| 2018-09-30 | $70.50M 10-Q · filed 2019-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |